Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

Prostate Cancer

Free Subscription 10.03.2025 1 AJR Am J Roentgenol 4 Anticancer Res 2 BJU Int 2 BMC Urol 2 BMJ Oncol 1 Br J Cancer 1 Cancer 1 Clin Cancer Res 1 Eur Urol 2 Int J Urol 1 J Clin Oncol 1 J Natl Cancer Inst 3 J Nucl Med 4 J Urol 4 Lancet Oncol 1 Oncogene 3 Prostate 1 Radiol Artif Intell

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DIAS AB, Chang SD, Fennessy FM, Ghafoor S, et al
   New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2024 Apr 3. doi: 10.2214/AJR.24.30956.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. HIRATA J, Hara T, Jimbo N, Ueki H, et al
   Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies.
   Anticancer Res. 2025;45:1137-1147.
   PubMed         Abstract available
   
   
3. HSU JY, Ou HC, Ou YC, Lin YS, et al
   Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.
   Anticancer Res. 2025;45:1281-1289.
   PubMed         Abstract available
   
   
4. NIEDER C, Haukland EC, Stanisavljevic L, Mannsaker B, et al
   Radiotherapy for Bone Metastases in Patients With Excellent Performance Status: Patterns of Care and Prognostic Factors for Survival.
   Anticancer Res. 2025;45:1149-1158.
   PubMed         Abstract available
   
   
5. WU J, Lagunas AM, Crowe DL
   DNA Ligase 4 Inhibition Sensitizes Prostate Cancer to Immune Checkpoint Blockade In Vivo.
   Anticancer Res. 2025;45:883-896.
   PubMed         Abstract available
   
   

   
   BJU Int

6. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
   Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
   BJU Int. 2023;132:568-574.
   PubMed         Abstract available
   
   
7. KAM J, Chalasani V, Goolam AS, Bergersen P, et al
   Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.
   BJU Int. 2025 Mar 6. doi: 10.1111/bju.16654.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. PENG Y, Wei C, Li Y, Zhao F, et al
   Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings.
   BMC Urol. 2025;25:42.
   PubMed         Abstract available
   
   
9. MAKELA L, Mikkola A, Petas A, Visapaa H, et al
   Urinary function, sexual function and quality of life after prostate low-dose-rate brachytherapy: a retrospective analysis.
   BMC Urol. 2025;25:40.
   PubMed         Abstract available
   
   

   
   BMJ Oncol

10. EVANS DG, Burghel G, Schlecht H, Sachdeva A, et al
    UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results.
    BMJ Oncol. 2025;4:e000592.
    PubMed         Abstract available
    
    
11. URABE F, Takemura K
    Evaluating the genetic landscape of prostate cancer: new insights from BRCA1/2, ATM and CDK12 mutations.
    BMJ Oncol. 2025;4:e000717.
    PubMed        
    
    

    
    Br J Cancer

12. LI GX, Ma B, Zhang S, Liu R, et al
    EphB4-ephrin-B2 are targets in castration resistant prostate cancer.
    Br J Cancer. 2025 Mar 5. doi: 10.1038/s41416-025-02942.
    PubMed         Abstract available
    
    

    
    Cancer

13. SEBASTIAN NT, Patil D, Patel PR, Jani AB, et al
    Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
    Cancer. 2025;131:e35795.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

14. HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al
    Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.
    Clin Cancer Res. 2025;31:936-948.
    PubMed         Abstract available
    
    

    
    Eur Urol

15. TAHA T, Koster KL, de Bono JS
    T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead.
    Eur Urol. 2025 Mar 5:S0302-2838(25)00147-2. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Int J Urol

16. ONISHI K, Nakai Y, Tachibana A, Nishimura N, et al
    Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70018.
    PubMed         Abstract available
    
    
17. SEKITO T, Sadahira T
    Editorial Comment on Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70035.
    PubMed        
    
    

    
    J Clin Oncol

18. PETRYLAK DP, Ratta R, Matsubara N, Korbenfeld E, et al
    Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
    J Clin Oncol. 2025 Mar 5:JCO2401283. doi: 10.1200/JCO-24-01283.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

19. SEKAR RR, Zebib L, Stensland KD, Herrel LA, et al
    Structural inequities in the availability of prostate cancer clinical trial opportunities.
    J Natl Cancer Inst. 2025 Feb 26:djaf047. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

20. FOXTON C, Waldron B, Veggerby Gronlund R, Simon JJ, et al
    Preclinical Evaluation of (177)Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.
    J Nucl Med. 2025 Mar 6:jnumed.124.268508. doi: 10.2967/jnumed.124.268508.
    PubMed         Abstract available
    
    
21. MORAITIS A, Kahl T, Kandziora J, Jentzen W, et al
    Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy.
    J Nucl Med. 2025 Feb 6:jnumed.124.268719. doi: 10.2967/jnumed.124.268719.
    PubMed         Abstract available
    
    
22. JOHNSTONE CN, Osellame LD, Cao Z, McDonald AF, et al
    DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of (177)Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    J Nucl Med. 2025;66:385-390.
    PubMed         Abstract available
    
    

    
    J Urol

23. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:538-540.
    PubMed        
    
    
24. ZHANG F, Li S
    Letter: A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004414. doi: 10.1097/JU.0000000000004414.
    PubMed        
    
    
25. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025 Mar 5:101097JU0000000000004491. doi: 10.1097/JU.0000000000004491.
    PubMed        
    
    
26. BORDE T, Varble NA, Hazen LA, Saccenti L, et al
    Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes.
    J Urol. 2025;213:428-436.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

27. WEI C, Wei W
    Dural metastasis of prostate cancer resembling meningioma.
    Lancet Oncol. 2025;26:e181.
    PubMed        
    
    
28. MARVASO G, Corrao G, Zaffaroni M, Vincini MG, et al
    ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.
    Lancet Oncol. 2025;26:300-311.
    PubMed         Abstract available
    
    
29. KISHAN AU, Valle LF
    Destroy or delay: hormonal therapy in oligometastatic prostate cancer.
    Lancet Oncol. 2025;26:266-267.
    PubMed        
    
    
30. NIKITAS J, Jamshidian P, Tree AC, Hall E, et al
    The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.
    Lancet Oncol. 2025;26:378-386.
    PubMed         Abstract available
    
    

    
    Oncogene

31. YIN L, Dai Y, Wang Y, Liu S, et al
    A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.
    Oncogene. 2025 Mar 6. doi: 10.1038/s41388-025-03328.
    PubMed         Abstract available
    
    

    
    Prostate

32. CHEN G, Li Y, Geng S, Lv L, et al
    Evaluating the Heterogeneity of Advanced Prostate Cancer by (18)F-DCFPyL and (18)F-FDG PET/CT in a Prospective Cohort.
    Prostate. 2025 Mar 5. doi: 10.1002/pros.24881.
    PubMed         Abstract available
    
    
33. SHI Y, Wei X, Zhao F, Chen J, et al
    The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate.
    Prostate. 2025 Mar 4:e24869. doi: 10.1002/pros.24869.
    PubMed         Abstract available
    
    
34. ROBINSON E, Kinsella N, Ap Dafydd D, Shur J, et al
    Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.
    Prostate. 2025 Mar 3. doi: 10.1002/pros.24886.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

35. GUNDOGDU B, Chatterjee A, Medved M, Bagci U, et al
    Physics-Informed Autoencoder for Prostate Tissue Microstructure Profiling with Hybrid Multidimensional MRI.
    Radiol Artif Intell. 2025 Feb 5:e240167. doi: 10.1148/ryai.240167.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.